JP7298048B2 - グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー - Google Patents

グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー Download PDF

Info

Publication number
JP7298048B2
JP7298048B2 JP2019511909A JP2019511909A JP7298048B2 JP 7298048 B2 JP7298048 B2 JP 7298048B2 JP 2019511909 A JP2019511909 A JP 2019511909A JP 2019511909 A JP2019511909 A JP 2019511909A JP 7298048 B2 JP7298048 B2 JP 7298048B2
Authority
JP
Japan
Prior art keywords
cyclic monophosphate
guanosine
cgmp
phenyl
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526576A5 (enExample
JP2019526576A (ja
Inventor
ハンス－ゴットフリート ゲニーサー
フランク シュヴェーデ
アンドレアス レンチュ
ヴァレリア マリゴ
Original Assignee
ミレカ メディシンズ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミレカ メディシンズ ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ミレカ メディシンズ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2019526576A publication Critical patent/JP2019526576A/ja
Publication of JP2019526576A5 publication Critical patent/JP2019526576A5/ja
Priority to JP2023010090A priority Critical patent/JP2023102288A/ja
Application granted granted Critical
Publication of JP7298048B2 publication Critical patent/JP7298048B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019511909A 2016-08-31 2017-08-31 グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー Active JP7298048B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023010090A JP2023102288A (ja) 2016-08-31 2023-01-26 グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16186700.7 2016-08-31
EP16186700 2016-08-31
PCT/EP2017/071859 WO2018041942A1 (en) 2016-08-31 2017-08-31 New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023010090A Division JP2023102288A (ja) 2016-08-31 2023-01-26 グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー

Publications (3)

Publication Number Publication Date
JP2019526576A JP2019526576A (ja) 2019-09-19
JP2019526576A5 JP2019526576A5 (enExample) 2020-10-08
JP7298048B2 true JP7298048B2 (ja) 2023-06-27

Family

ID=56990226

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511909A Active JP7298048B2 (ja) 2016-08-31 2017-08-31 グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー
JP2023010090A Pending JP2023102288A (ja) 2016-08-31 2023-01-26 グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023010090A Pending JP2023102288A (ja) 2016-08-31 2023-01-26 グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー

Country Status (4)

Country Link
US (2) US20210317156A1 (enExample)
EP (1) EP3507295A1 (enExample)
JP (2) JP7298048B2 (enExample)
WO (1) WO2018041942A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7161760B2 (ja) * 2017-02-03 2022-10-27 国立大学法人東北大学 複素環化合物
CA3267932A1 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARCEL AND IMPLANT FORMULATIONS FOR ANALOGUE CGMP THERAPY
CN117946407B (zh) * 2023-12-18 2025-11-18 浙江大学 基于Zn-MOFs构建的双模式光学探针及制备与对HOCl和H2O2的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521465A (ja) 2007-03-12 2010-06-24 ネクター セラピューティックス 複合体のデノボ合成
WO2016118932A1 (en) 2015-01-23 2016-07-28 Dynavax Technologies Corporation Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
WO1999025384A2 (en) 1997-11-17 1999-05-27 University Of Miami Multimeric tethered ligands and their use in receptor-ligand interactions
WO2012130829A1 (en) 2011-03-29 2012-10-04 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New boranophosphate analogues of cyclic nucleotides
MX379365B (es) 2014-06-30 2025-03-11 Tarveda Therapeutics Inc Conjugados y partículas direccionados y formulaciones de estos.
CA3069586A1 (en) * 2016-07-11 2018-01-18 Mireca Medicines Gmbh New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521465A (ja) 2007-03-12 2010-06-24 ネクター セラピューティックス 複合体のデノボ合成
WO2016118932A1 (en) 2015-01-23 2016-07-28 Dynavax Technologies Corporation Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature，1998年，Vol.395, No.6703，p.710-3

Also Published As

Publication number Publication date
US20230242568A1 (en) 2023-08-03
US20210317156A1 (en) 2021-10-14
WO2018041942A1 (en) 2018-03-08
JP2023102288A (ja) 2023-07-24
WO2018041942A9 (en) 2019-01-17
EP3507295A1 (en) 2019-07-10
US12384813B2 (en) 2025-08-12
JP2019526576A (ja) 2019-09-19

Similar Documents

Publication Publication Date Title
JP2023102288A (ja) グアノシン－３’，５’－環状一リン酸の新たなポリマー結合マルチマー
JP7672368B2 (ja) ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー
JP6574821B2 (ja) カルボキシｘローダミン類似体
AU2009323766B2 (en) Method for the synthesis of phosphorus atom modified nucleic acids
JP2018507863A (ja) 共役基を含む水溶性蛍光染料または有色染料
JP6876002B2 (ja) 機能的要素を共有結合により係留させるための細胞透過性、細胞適合性、かつ開裂可能であるリンカー
CN107580618A (zh) 超亮二聚或多聚染料
WO2014039715A1 (en) Methods and compositions for site-specific labeling of peptides and proteins
Wang et al. Advanced aqueous-phase phosphoramidation reactions for effectively synthesizing peptide–oligonucleotide conjugates trafficked into a human cell line
EP3137898A2 (en) Fluorescent molecular sensor for targeting changes in protein surfaces, and methods of use thereof
CA2730083A1 (en) Stimulus-responsive apta-chelamers
Jankowska-Anyszka et al. Synthesis of a new class of ribose functionalized dinucleotide cap analogues for biophysical studies on interaction of cap-binding proteins with the 5′ end of mRNA
Tanaka et al. Template-assisted and self-activating clicked peptide as a synthetic mimic of the SH2 domain
JP6276390B2 (ja) 化合物の細胞膜透過の方法
Tran et al. Dual-Function Probes to Tag, Isolate and Identify Nucleobase-Binding Proteins
WO2017061288A1 (ja) チロシンホスファターゼ及びチロシンキナーゼ活性の測定方法
Omar Synthesis & Characterization of N-methylpyrrole Containing Distamycin A Analogues Which Have Potential Biological Activity
PL243397B1 (pl) Reaktywne pochodne barwników Safirinium oraz ich zastosowanie

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221227

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230126

R150 Certificate of patent or registration of utility model

Ref document number: 7298048

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150